Management of metastatic renal cell carcinoma in patients with poor prognosis

References

• JemalASiegelRWardEHaoYXuJThunMJCancer statistics, 2009CA Cancer J Clin200959422524919474385
   PubMed Web of Science ®Google Scholar
• LamJSLeppertJTBelldegrunASFiglinRANovel approaches in the therapy of metastatic renal cell carcinomaWorld J Urol200523320221215812574
   PubMed Web of Science ®Google Scholar
• JanzenNKKimHLFiglinRABelldegrunASSurveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent diseaseUrol Clin North Am200330484385214680319
   PubMed Web of Science ®Google Scholar
• MotzerRJBacikJMurphyBARussoPMazumdarMInterferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinomaJ Clin Oncol200220128929611773181
   PubMed Web of Science ®Google Scholar
• MotzerRJBanderNHNanusDMRenal-cell carcinomaN Engl J Med1996335128658758778606
   PubMed Web of Science ®Google Scholar
• MotzerRJMazumdarMBacikJBergWAmsterdamAFerraraJSurvival and prognostic stratification of 670 patients with advanced renal cell carcinomaJ Clin Oncol19991782530254010561319
   PubMed Web of Science ®Google Scholar
• FlaniganRCSalmonSEBlumensteinBANephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancerN Engl J Med2001345231655165911759643
   PubMed Web of Science ®Google Scholar
• MickischGHGarinAvan PoppelHde PrijckLSylvesterRRadical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trialLancet2001358928696697011583750
   PubMed Web of Science ®Google Scholar
• MekhailTMAbou-JawdeRMBoumerhiGValidation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinomaJ Clin Oncol200523483284115681528
   PubMed Web of Science ®Google Scholar
• NegrierSGomezFDouillardJYPrognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’ImmunotherapieWorld J Urol200523316116515711829
   PubMed Web of Science ®Google Scholar
• ChoueiriTKGarciaJAElsonPClinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapyCancer2007110354355017577222
   PubMed Web of Science ®Google Scholar
• HengDYXieWReganMMPrognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyJ Clin Oncol2009
   Web of Science ®Google Scholar
• ZismanAPantuckAJDoreyFImproved prognostication of renal cell carcinoma using an integrated staging systemJ Clin Oncol20011961649165711250993
   PubMed Web of Science ®Google Scholar
• PatardJJLerayERioux-LeclercqNPrognostic value of histologic subtypes in renal cell carcinoma: a multicenter experienceJ Clin Oncol200523122763277115837991
   PubMed Web of Science ®Google Scholar
• FrankIBluteMLChevilleJCLohseCMWeaverALZinckeHAn outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN scoreJ Urol200216862395240012441925
   PubMed Web of Science ®Google Scholar
• LeibovichBCHanKRBuiMHScoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trialsCancer200398122566257514669275
   PubMed Web of Science ®Google Scholar
• ManiSToddMBKatzKPooWJPrognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiersJ Urol1995154135407539867
   PubMed Web of Science ®Google Scholar
• de Peralta-VenturinaMMochHAminMSarcomatoid differentiation in renal cell carcinoma: a study of 101 casesAm J Surg Pathol200125327528411224597
   PubMed Web of Science ®Google Scholar
• EscudierBDrozJPRollandFDoxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer CentersJ Urol2002168395996112187199
   PubMed Web of Science ®Google Scholar
• ChevilleJCLohseCMZinckeHWeaverALBluteMLComparisons of outcome and prognostic features among histologic subtypes of renal cell carcinomaAm J Surg Pathol200327561262412717246
   PubMed Web of Science ®Google Scholar
• KimHLSeligsonDLiuXUsing tumor markers to predict the survival of patients with metastatic renal cell carcinomaJ Urol200517351496150115821467
   PubMed Web of Science ®Google Scholar
• LeibovichBCSheininYLohseCMCarbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinomaJ Clin Oncol200725304757476417947723
   PubMed Web of Science ®Google Scholar
• BuiMHVisapaaHSeligsonDPrognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinomaJ Urol20041716 Pt 12461246615126876
   PubMed Web of Science ®Google Scholar
• BuiMHSeligsonDHanKRCarbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapyClin Cancer Res20039280281112576453
   PubMed Web of Science ®Google Scholar
• AtkinsMReganMMcDermottDCarbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancerClin Cancer Res200511103714372115897568
   PubMed Web of Science ®Google Scholar
• ChoueiriTKVaziriSAJaegerEvon Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinomaJ Urol20081803860865 discussion 865–86618635227
   PubMed Web of Science ®Google Scholar
• SmitsKMSchoutenLJvan DijkBAGenetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosisClin Cancer Res200814378278718245539
   PubMed Web of Science ®Google Scholar
• PatardJJFergelotPKarakiewiczPILow CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinomaInt J Cancer2008123239540018464292
   PubMed Web of Science ®Google Scholar
• HoriguchiAOyaMUchidaAMarumoKMuraiMElevated Akt activation and its impact on clinicopathological features of renal cell carcinomaJ Urol2003169271071312544348
   PubMed Web of Science ®Google Scholar
• HoffmannNESheininYLohseCMExternal validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinomaCancer200811271471147918260086
   PubMed Web of Science ®Google Scholar
• ThompsonRZXHohseCMSerum soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage2008 Genitourinary Cancers Symposium2008 abstr 383.
   Google Scholar
• ThompsonRH ZXLohseCMEvaluation of soluble B7x as a serum marker in patients with clear cell renal cell carcinomaJ Clin Oncol2008 ASCO Annual Meeting2008520 suppl abstr 5052.
   Google Scholar
• NegrierSPerolDRavaudAMedroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trialCancer2007110112468247717932908
   PubMed Web of Science ®Google Scholar
• AtkinsMBHidalgoMStadlerWMRandomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinomaJ Clin Oncol200422590991814990647
   PubMed Web of Science ®Google Scholar
• HudesGCarducciMTomczakPTemsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med2007356222271228117538086
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet2008372963744945618653228
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEBevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206J Clin Oncol200826335422542818936475
   PubMed Web of Science ®Google Scholar
• SternbergCNSzczylikCLeeEA randomized, double-blind, phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC)J Clin Oncol20092715s Abstr 5021.
   Google Scholar
• MotzerRJHutsonTETomczakPOverall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaJ Clin Oncol200927223584359019487381
   PubMed Web of Science ®Google Scholar
• MotzerRJMichaelsonMDRedmanBGActivity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinomaJ Clin Oncol2006241162416330672
   PubMed Web of Science ®Google Scholar
• GoreMESzczylikCPortaCSafety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trialLancet Oncol200910875776319615940
   PubMed Web of Science ®Google Scholar
• RiniBIVogelzangNJDumasMCWadeJL3rdTaberDAStadlerWMPhase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancerJ Clin Oncol200018122419242610856102
   PubMed Web of Science ®Google Scholar
• NanusDMGarinoAMilowskyMILarkinMDutcherJPActive chemotherapy for sarcomatoid and rapidly progressing renal cell carcinomaCancer200410171545155115378501
   PubMed Web of Science ®Google Scholar
• N HaasJMPinsMLiuGECOG 8802: Phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid featuresGenitourinary Cancers Symposium2009 abstr 285.
   Google Scholar
• MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med2007357262666267618160686
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• GiantonioBJCatalanoPJMeropolNJBevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol200725121539154417442997
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAilJ Clin Oncol20092781227123419188680
   PubMed Web of Science ®Google Scholar
• KreislTNKimLMooreKPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol200927574074519114704
   PubMed Web of Science ®Google Scholar
• MichaelsonASRyanDMcDermottDA phase I study of sunitinib in combination with gemcitabine in advanced renal cell carcinoma and other solid tumorsGenitourinary Cancers Symposium 2008 abstr 362.
   Google Scholar
• SchoutenLJRuttenJHuveneersHATwijnstraAIncidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanomaCancer200294102698270512173339
   PubMed Web of Science ®Google Scholar
• PatynaSLairdADMendelDBSU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activityMol Cancer Ther2006571774178216891463
   PubMed Web of Science ®Google Scholar
• RiechelmannRPChinSWangLSorafenib for metastatic renal cancer: the Princess Margaret experienceAm J Clin Oncol200831218218718391604
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med2007356212513417215530
   PubMed Web of Science ®Google Scholar
• JJ KnoxRAFStadlerWMMcDermottDFThe Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacyJ Clin Oncol2007 ASCO Annual Meeting Proceedings200725 18S620 Supplement
   Google Scholar
• BukowskiRMPrognostic factors for survival in metastatic renal cell carcinoma: update 2008Cancer200911510 Suppl2273228119402065
   PubMed Web of Science ®Google Scholar